Artemis Medicare Services Limited has notified the stock exchanges of a change in its board composition, disclosing that Mr. Sunil Tandon has ceased to be a Director of the company. The development was communicated pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was filed by Company Secretary and Compliance Officer Poonam Makkar on May 10, 2026.

Board Change: Cessation of Independent Director

Mr. Sunil Tandon (DIN: 08342585) stepped down from the board of Artemis Medicare Services upon the completion of his tenure as an Independent Director on May 9, 2026. The cessation was a result of the natural expiry of his term and does not indicate any other circumstance. The company has disclosed the required details in accordance with Schedule III of the SEBI Listing Regulations.

Key Details of the Change

The following information has been provided by the company as required under Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Regulatory Compliance

The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited in compliance with applicable listing regulations. The filing was signed and submitted by Poonam Makkar, Company Secretary and Compliance Officer of Artemis Medicare Services, on May 10, 2026. No further details regarding a replacement appointment were disclosed as part of this filing.

Artemis Medicare Services Limited has notified the stock exchanges of an amendment to its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended Code was approved by the Board of Directors on May 8, 2026, and has been uploaded on the company's website at www.artemishospitals.com/investors . The intimation was submitted by Poonam Makkar, Company Secretary and Compliance Officer.

Code Overview and Effective Dates

The Code was originally adopted at a Board meeting and has since been periodically reviewed and updated. The key dates associated with the Code are as follows:

Objective and Scope

The Code is designed to ensure timely and adequate disclosure of UPSI that may impact the price of the company's securities, while maintaining uniformity, transparency, and fairness in dealings with all stakeholders. It also aims to preserve the confidentiality of UPSI and prevent its misuse. The Code applies to all persons within the organisation who may come into possession of price-sensitive information.

Key Norms for Fair Disclosure

The amended Code sets out a comprehensive framework of norms governing the handling and dissemination of UPSI. The principal requirements include:

• Prompt public disclosure of UPSI that would impact price discovery, as soon as credible and concrete information comes into being
• Uniform and universal dissemination of UPSI to all Stock Exchanges and on the company's official website to avoid selective disclosure
• Restricted external communication, with only designated Authorised Spokespersons permitted to discuss company matters with media, investors, and the investment community
• Prompt remediation in cases where UPSI is disclosed selectively or inadvertently, through immediate dissemination to Stock Exchanges and the company's website
• Fair and appropriate responses to queries on news reports and requests for verification of market rumours from regulatory authorities
• Need-to-know basis handling of all UPSI within the organisation

Authorised Spokespersons

Unless otherwise approved by the Managing Director, only individuals in the following designated positions are authorised to communicate company matters externally:

• Chairman
• Managing Director
• Chief Financial Officer
• Chief Business Officer
• Head – Investor Relations, M&A and Organization Growth Strategy
• Chief People Officer

Analyst Interactions and Record-Keeping

The Code specifies that the company shall provide only public information to analysts, research personnel, investor groups, and institutional investors. At least two Authorised Representatives are required to be present at all meetings and conference calls with analysts to prevent misquoting or misrepresentation. Transcripts and recordings of such meetings are to be uploaded on the company's website in accordance with applicable laws.

Confidentiality Safeguards and Legitimate Purpose Policy

Persons privy to UPSI are required to adopt specific safeguards to preserve confidentiality, including maintaining secure physical files, password-protected computer access, and deletion or destruction of confidential files after use. The Code also incorporates a Policy for Determination of Legitimate Purpose, framed under Regulation 3(2A) of the SEBI Insider Trading Regulations. This policy outlines factors to assess whether sharing of UPSI in a given instance constitutes a legitimate purpose, including whether the sharing is in the ordinary course of business, in the best interests of the company, or required to fulfil legal or contractual obligations. A structured digital database is to be maintained internally—with time stamping and audit trails—recording the nature of UPSI shared and the identities of persons involved, including their Permanent Account Numbers or other authorised identifiers.